2-amino-4-[N,N-bis(2-hydroxyethyl)amino]-6-(2,5-dichlorophenyl)-1,3,5-triazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-4-[N,N-bis(2-hydroxyethyl)amino]-6-(2,5-dichlorophenyl)-1,3,5-triazine
• 英文别名: 2-[[4-amino-6-(2,5-dichlorophenyl)-1,3,5-triazin-2-yl]-(2-hydroxyethyl)amino]ethanol
• 化学式: C₁₃H₁₅Cl₂N₅O₂
• 分子量: 344.2
• InChiKey: YIGHRJFNYCYMQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-amino-4-chloro-6-(2,5-dichlorophenyl)-1,3,5-triazine 、 二乙醇胺 在 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-amino-4-[N,N-bis(2-hydroxyethyl)amino]-6-(2,5-dichlorophenyl)-1,3,5-triazine
  参考文献：
  名称：

  Triazine derivative and medicine

  摘要：

  该发明涉及一种药物组合物，其包括以下一般式的三嗪衍生物\x9bI! ##STR1## 或其溶剂化物，或其盐，作为活性成分。在上述式中，R.sup.1和R.sup.2可以相同也可以不同，每个代表氢，未取代或取代的烷基芳基，或烯基，或者共同代表与相邻氮原子结合的环状氨基（NR.sup.1 R.sup.2）。该环状氨基除了相邻氮原子外，还可以包含氮、氧或硫作为环成员，并且可能进一步取代。不包括NR.sup.1 R.sup.2为NH.sub.2的情况。该发明的化合物可用作治疗肝炎的治疗药物。

  公开号：

  US05962453A1

文献信息

• Triazine derivative and medicine
  申请人：Nippon Shinyaku Co. Ltd.

  公开号：US05962453A1

  公开（公告）日：1999-10-05

  The invention relates to a medicinal composition comprising a triazine derivative of the following general formula \x9bI! ##STR1## or a solvate thereof, or a salt thereof, as an active ingredient. In the above formula, R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, unsubstituted or substituted alkyl aralkyl, or alkenyl, or jointly represent cyclic amino (NR.sup.1 R.sup.2) in combination with the adjacent nitrogen atom. The cyclic amino may contain nitrogen, oxygen, or sulfur as a ring member in addition to the adjacent nitrogen and may be further substituted. Excluded is the case in which NR.sup.1 R.sup.2 is NH.sub.2. The compound of the invention is useful as a therapeutic drug for hepatitis.

  该发明涉及一种药物组合物，其包括以下一般式的三嗪衍生物\x9bI! ##STR1## 或其溶剂化物，或其盐，作为活性成分。在上述式中，R.sup.1和R.sup.2可以相同也可以不同，每个代表氢，未取代或取代的烷基芳基，或烯基，或者共同代表与相邻氮原子结合的环状氨基（NR.sup.1 R.sup.2）。该环状氨基除了相邻氮原子外，还可以包含氮、氧或硫作为环成员，并且可能进一步取代。不包括NR.sup.1 R.sup.2为NH.sub.2的情况。该发明的化合物可用作治疗肝炎的治疗药物。
• Neovascularization inhibitor
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：US05962454A1

  公开（公告）日：1999-10-05

  The invention relates to a neovascularization inhibitor composition comprising a compound of the following general formula \x9bI! or a salt thereof, or a solvate thereof, as an active ingredient, ##STR1## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.

  该发明涉及一种新生血管抑制剂组合物，其包括以下通用公式\x9bI!的化合物或其盐或溶剂化合物作为活性成分，其中R.sup.1代表氢、可选地取代的烷基、芳基烷基、芳基烯基或芳基；R.sup.2代表可选地取代的烷基、芳基烷基、芳基烯基或芳基；或者R.sup.1和R.sup.2共同和与相邻的N原子一起，即以NR.sup.1 R.sup.2的形式，代表一个4-至8-成员环氨基组，该环氨基组可选地含有氮、氧或硫作为环原子，除了所述的N原子外，还可选地进一步取代。
• TRIAZINE DERIVATIVE AND MEDICINE
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0775487A1

  公开（公告）日：1997-05-28

  A medicine containing as the active ingredient a triazine derivative represented by general formula (I), a solvate thereof, or a salt thereof and being useful as a hepatitis remedy, wherein R1 and R2 represent each independently hydrogen or (un)substituted alkyl, aralkyl or alkenyl, or NR1R2 represents a cyclic amino group which may bear, in addition to the pertinent nitrogen atom, nitrogen, oxygen or sulfur as the ring atom and may be substituted, provided the case where NR1R2 represents NH2 is excluded.

  一种含有通式(I)代表的三嗪衍生物、其溶液或其盐作为有效成分并可用于治疗肝炎的药物，其中R1和R2各自独立地代表氢或(未)取代的烷基、芳烷基或烯基，或NR1R2代表环状氨基，其环状原子除了相关的氮原子外，还可以是氮、氧或硫，并且可以被取代，但不包括NR1R2代表NH2的情况。
• NEOVASCULARIZATION INHIBITOR
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0821961A1

  公开（公告）日：1998-02-04

  The invention relates to a neovascularization inhibitor composition comprising a compound of the following general formula [I] or a salt thereof, or a solvate thereof, as an active ingredient, wherein R1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; R2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; or R1 and R2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR1R2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.

  本发明涉及一种新生血管抑制剂组合物，其活性成分包括下通式[I]的化合物或其盐或其溶液、 其中R1代表氢、任选取代的烷基、芳烷基、芳烯基或芳基；R2代表任选取代的烷基、芳烷基、芳烯基或芳基；或R1和R2连在一起并与相邻的N原子一起，即以NR1R2的形式，代表除所述N原子外任选含有氮、氧或硫作为环成员并任选被进一步取代的4至8元环状氨基。
• REMEDY FOR PANCREATITIS
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0813874A1

  公开（公告）日：1997-12-29

  The invention relates to a therapeutic drug for pancreatitis which comprises a compound of the following general formula [I] or a salt thereof, or a solvate thereof. In the above formula, R1 and R2 may be the same or different and each represents hydrogen, alkyl which may be substituted, aralkyl, arylalkenyl, or aryl, or R1 and R2 taken together with the adjacent N atom, i.e. in the form of NR1R2, represent a 4- through 8-membered cyclic amino group, which cyclic amino group may contain nitrogen, oxygen, or sulfur as a ring member in addition to the above-mentioned N atom and may be further substituted.

  本发明涉及一种治疗胰腺炎的药物，它包括以下通式[I]的化合物或其盐，或其溶液。 在上式中，R1和R2可以相同或不同，各自代表氢、可被取代的烷基、芳烷基、芳烯基或芳基，或者R1和R2与相邻的N原子一起，即以NR1R2的形式，代表4-至8元环氨基，该环氨基除上述N原子外，还可含有氮、氧或硫作为环成员，并可进一步被取代。